5 leading Analysts; and top management from 4 Sector Firms
examine this vital industry in this 30 page report from The Wall Street Transcript.
Order this Report
Big Pharma Moves Toward Orphan Drugs & Emerging Markets Damien Conover - Morningstar, Inc.
Innovation Is Key Theme in Biotechnology Ravi Mehrotra - Credit Suisse
Orphan Drugs Bypass Macroeconomic Headwinds Ian Somaiya - Piper Jaffray & Co.
Product Pipeline & Diversification Are Key in Pharma Jon LeCroy - MKM Partners
Innovation in Cardiovascular and Hepatic Devices and Drugs Duane Nash - Wedbush Securities
CEO Interviews (average 2,500 words): top management from 4 Sector Firms examine the outlook for its company and its sector. Firms interviewed include: Acura Pharmaceuticals, Inc., International Stem Cell Corporation, Marshall Edwards, Inc., and Tranzyme, Inc.
Topics covered: Orphan Drug and Biologics Manufacturing - U.S. and European Drug Pricing - Biotechnology and Pharmaceutical Companies Valuation - Domestic Regulatory Uncertainty
ORDER THIS REPORT NOW! CLICK HERE
Companies covered: Eli Lilly (LLY); InterMune's (ITMN); Thoratec (THOR); Abbott (ABT); Acura Pharmaceuticals (ACUR); Alexion (ALXN); Amgens (AMGN); AstraZeneca (AZN); Biogen Idec (BIIB); Biomarin (BMRN); Bristol-Myers (BMY); Cardica (CRDC); Celgenes (CELG); Dendreon's (DNDN); Endologix (ELGX); Gileads (GILD); GlaxoSmithKline (GSK); Heartware International (HTWR); Human Genome Sciences' (HGSI); Idenix (IDIX); Incyte (INCY); Inhibitex (INHX); International Stem Cell (ISCO); J&J (JNJ); Marshall Edwards (MSHL); Merck (MRK); Neurocrine (NBIX); Novartis (NVS); Pfizer (PFE); Pharmasset (VRUS); Roche (RO.SW); Sanofi (SNY); Targacept (TRGT); Tranzyme, Inc. (TZYM).
